Study of 2% Ganciclovir Eye Drops to Treat Cytomegalovirus Retinitis in Patients Aged 2 to 80 Years

What this Trial Is About

This research aims to evaluate the use of high concentration 2% Ganciclovir Eye Drops in treating cytomegalovirus retinitis, a serious eye infection. The study is a single-center, prospective trial where patients diagnosed with this condition are carefully monitored. The study follows ethical guidelines, and participants provide informed consent after being fully informed about the treatment and potential risks. Participants receive 2% Ganciclovir Eye Drops with a specific dosing schedule 10 times per day for the first two weeks, then 8 times per day for the following two weeks, 6 times per day for the next two weeks, and finally 4 times per day for more than six weeks. The study focuses on one experimental group using this eye drop therapy. Throughout the study, researchers assess various eye health measures including visual acuity, eye pressure, corneal condition, inflammation, optical coherence tomography, and wide-angle fundus imaging. The main outcome measured is the condition of fundus lesions over 24 weeks, along with changes in best corrected visual acuity. Safety and effectiveness are monitored during this period, with the total participation lasting up to 24 weeks.

Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis